Search results
Results from the WOW.Com Content Network
Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. [5] Specifically it is used for open angle glaucoma when other agents are not sufficient. [5] [6] It may also be used to increase the size of the eyelashes.
The FP receptor agonist, bimatoprost, in the form of an 0.03% ophthalmic solution termed Latisse, is approved by the US Food and Drug Administration to treat hypotrichosis of the eyelashes, in particular to darken and lengthen eyelashes for cosmetic purposes. [59] Also, bimatoprost may be used to treat small or underdeveloped eyelashes. [60] [61]
No formal interaction studies have been done with bimatoprost/timolol eye drops. As timolol (in tablet form) can be used to lower blood pressure and heart rhythm, it might add to the effect of other antihypertensive (pressure lowering) drugs. Also, drugs that block the liver enzyme CYP2D6 may increase the effects of timolol. [4]
There was a clinical trial in 2011 that tested an eyelash gel called bimatoprost. This gel enhanced the eyelashes in quantity and thickness. They tested this on 20 breast cancer patients who were undergoing chemotherapy. Results seemed positive, in that the group of people who used the gel had growth of eyelashes after the chemotherapy drugs. [13]
Latisse was introduced in the first quarter of 2009 by Allergan as the first drug to receive FDA approval for eyelash growth. Latisse is a solution of bimatoprost, a prostaglandin analog and the active component of the glaucoma medication Lumigan. According to Allergan, noticeable eyelash growth occurs within 16 weeks.
pigmentation of eyelashes, eyelid skin pigmentation, hyperemia (red eye), flu-like symptoms (joint/muscle pain and headache) Bimatoprost: Lumigan: Increased USO (uveoscleral outflow ) Once daily: blurred vision, eyelid redness, eye discomfort, permanently darken iris, darken/thicken eyelashes Travoprost: Travatan: Increased USO (uveoscleral ...
This work led to the development of prodrugs of PGF2α, including latanoprost, an isopropyl analogue of PGF2α, approved by the FDA in 1996, bimatoprost and travoprost, both approved in 2001, and tafluprost, approved in 2012. [1]
This page was last edited on 15 December 2021, at 11:09 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.